Sugi Predict

Sugi Predict / Compounds / SCHEMBL5598952

SCHEMBL5598952

SCHEMBL5598952

Cc1ccccc1/C=C/C(=O)/C=C/c1ccccc1C

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NFE2L2 Q16236 3/20 0.61
▸ NFKB1 P19838 3/20 0.61
▸ JUN P05412 1/20 0.61
▸ HSD11B1 P28845 1/20 0.59
▸ TFEB P19484 1/20 0.58
▸ ALDH1A1 P00352 3/20 0.52
▸ TSHR P16473 2/20 0.52
▸ MAPT P10636 3/20 0.50
▸ RAB9A P51151 3/20 0.50
▸ LMNA P02545 3/20 0.50
▸ CYP1A2 P05177 3/20 0.50
▸ CYP2D6 P10635 3/20 0.50
▸ SMN1; SMN2 Q16637 2/20 0.50
▸ KDM4E B2RXH2 2/20 0.50
▸ CYP2C9 P11712 2/20 0.50
▸ PLIN1 O60240 1/20 0.50
▸ F3 P13726 1/20 0.50
▸ RECQL P46063 1/20 0.50
▸ PLIN5 Q00G26 1/20 0.50
▸ ABHD5 Q8WTS1 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5598954 1.00 NFE2L2 (0.61) NFE2L2NFKB1JUNHSD11B1TFEB
SCHEMBL608507 0.87 JUN (0.54) NFE2L2NFKB1JUNHSD11B1TFEB
SCHEMBL16093028 0.86 NFE2L2 (0.84) NFE2L2NFKB1JUNTFEBALDH1A1
SCHEMBL11487985 0.85 NFE2L2 (0.46) NFE2L2NFKB1JUNHSD11B1TFEB
SCHEMBL78555 0.85 CA1 (0.62) NFKB1ALDH1A1TSHRMAPTRAB9A
SCHEMBL7899013 0.85 MAPT (0.66) NFE2L2NFKB1JUNHSD11B1TFEB
SCHEMBL78556 0.85 CA1 (0.62) NFKB1ALDH1A1TSHRMAPTRAB9A
SCHEMBL14279409 0.85 MAPT (0.66) NFE2L2NFKB1JUNHSD11B1TFEB
SCHEMBL2834883 0.85 MAPT (0.66) NFE2L2NFKB1JUNHSD11B1TFEB
SCHEMBL31422587 0.85 MAPT (0.66) NFE2L2NFKB1JUNHSD11B1TFEB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0368327-A2 Light-sensitive composition FUJI PHOTO FILM CO., LTD. (JP) 1990-05-16 — — EP claimed
JP-56169089-A — — None — — JP disclosed
US-20220152001-A1 HUMAN THERAPEUTIC AGENTS ANKH LIFE SCIENCES LIMITED (IE) 2022-05-19 — — US disclosed
US-20200383958-A1 HUMAN THERAPEUTIC AGENTS ANKH LIFE SCIENCES LIMITED (IE) 2020-12-10 — — US disclosed
US-10751330-B2 Human therapeutic agents ANKH LIFE SCIENCES LIMITED (IE) 2020-08-25 — — US disclosed
US-10744124-B2 Human therapeutic agents ANKH LIFE SCIENCES LIMITED (IE) 2020-08-18 — — US disclosed
US-20200147061-A1 HUMAN THERAPEUTIC AGENTS ANKH LIFE SCIENCES LIMITED (IE) 2020-05-14 — — US disclosed
CN-110996930-A Novel benzylidene acetone derivative and use thereof 韩药有限公司 2020-04-10 — — CN disclosed
US-10576067-B2 Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof ANKH LIFE SCIENCES LIMITED (IE) 2020-03-03 — — US disclosed
US-10471049-B2 Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof ANKH LIFE SCIENCES LIMITED (IE) 2019-11-12 — — US disclosed
US-20150011494-A1 THERAPEUTIC CURCUMIN DERIVATIVES STC.UNM 2015-01-08 — — US disclosed
US-8841326-B2 Therapeutic curcumin derivatives STC.UNM (US) 2014-09-23 — — US disclosed
US-8841326-B2 Therapeutic curcumin derivatives STC.UNM (US) 2014-09-23 — — US disclosed
US-8841326-B2 Therapeutic curcumin derivatives STC.UNM (US) 2014-09-23 — — US disclosed
US-20070060644-A1 Therapeutic curcumin derivatives STC.UNM 2007-03-15 — — US disclosed
US-20070060644-A1 Therapeutic curcumin derivatives STC.UNM 2007-03-15 — — US disclosed
US-20070060644-A1 Therapeutic curcumin derivatives STC.UNM 2007-03-15 — — US disclosed
US-20060276536-A1 Cancer treatment using curcumin derivatives STC.UNM 2006-12-07 — — US disclosed
JP-S56169089-A HEAT SENSITIVE RECORDER PENTEL KK 1981-12-25 — — JP disclosed
US-RE29358-E ANTI-MALARIA AND ANTI-TUBERCULOSIS AGENTS AMERICAN CYANAMID COMPANY (US) 1977-08-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10744124-B2 Human therapeutic agents INMT, HNMT, HASPIN NFE2L2 832/4885NFKB1 841/4885JUN 2377/4885
US-20070060644-A1 Therapeutic curcumin derivatives FABP2, GLS2, FABP1 NFE2L2 75/4885NFKB1 418/4885JUN 2204/4885
US-10751330-B2 Human therapeutic agents INMT, HNMT, HASPIN NFE2L2 832/4885NFKB1 841/4885JUN 2377/4885
US-20150011494-A1 THERAPEUTIC CURCUMIN DERIVATIVES FABP2, GLS2, FABP1 NFE2L2 75/4885NFKB1 418/4885JUN 2204/4885
US-20220152001-A1 HUMAN THERAPEUTIC AGENTS INMT, HNMT, HASPIN NFE2L2 832/4885NFKB1 841/4885JUN 2377/4885
US-10471049-B2 Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof INMT, HNMT, COMT NFE2L2 1139/4885NFKB1 1602/4885JUN 2579/4885
US-20200147061-A1 HUMAN THERAPEUTIC AGENTS INMT, HNMT, HASPIN NFE2L2 832/4885NFKB1 841/4885JUN 2377/4885
US-20200383958-A1 HUMAN THERAPEUTIC AGENTS INMT, HNMT, HASPIN NFE2L2 832/4885NFKB1 841/4885JUN 2377/4885
US-10576067-B2 Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof INMT, HNMT, COMT NFE2L2 1139/4885NFKB1 1602/4885JUN 2579/4885
US-20060276536-A1 Cancer treatment using curcumin derivatives BRCA1, VHL, TP53 NFE2L2 5/4885NFKB1 73/4885JUN 786/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.